臨床検査54巻4号

2010年04月発行

今月の主題 広義のアポリポ蛋白 各論 〈臨床検査への応用の可能性〉

パラオキソナーゼ1(PON1)

著者： 池田幸雄¹

所属機関： ¹高知記念病院糖尿病内科

ページ範囲：P.383 - P.388

　パラオキソナーゼ1(PON1)は分子量約43kDの糖蛋白で，肝で合成され，血中ではHDL上でアポ蛋白A-Iやアポ蛋白Jと結合して存在している．PON1はin vitroにおいてLDLやHDL自体の酸化を抑制する．PON1ノックアウトマウスでは高脂肪食により動脈硬化が進行しやすく，PON1を過剰発現させたトランスジェニックマウスではその逆の現象がみられる．臨床においてPON1の酵素活性や蛋白濃度の低下が心血管イベントや死亡の増加に関連することが明らかにされている．PON1の発現を調節することが可能となれば動脈硬化症の予防や治療に応用できる可能性があり，研究の進展が期待される．

参考文献

1) La Du BN：Human serum paraoxonase/arylesterase. In：Pharmacogenetics of Drug Metabolism(Kalow W, ed), Pergamon, New York, pp51-91, 1992

2) Khersonsky O, Tawfik DS：Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry　44：6371-6382, 2005

3) Mackness MI, Arrol S, Durrington PN：Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett　286：152-154, 1991

4) Costa LG, Cole TB, Jarvik GP, et al：Functional genomic of the paraoxonase(PON1)polymorphisms：effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med　54：371-392, 2003

5) Rozenberg O, Rosenblat M, Coleman R, et al：Paraoxonase(PON1)deficiency is associated with increased macrophage oxidative stress：studies in PON1-knockout mice. Free Radic Biol Med　34：774-784, 2003

6) Shih DM, Gu L, Xia YR, et al：Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature　394：284-287, 1998

7) Tward A, Xia YR, Wang XP, et al：Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation　106：484-490, 2002

8) Humbert R, Adler DA, Disteche CM, et al：The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet　3：73-76, 1993

)gene and its association with PON1 expression. Atherosclerosis　150：295-298, 2000

10) Aviram M, Billecke S, Sorenson R, et al：Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities：selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol　18：1617-1624, 1998

11) Aviram M, Rosenblat M：Paraoxonase 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med　37：1304-1316, 2004

12) Mackness B, Hine D, Liu Y, et al：Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun　318：680-683, 2004

13) Ikeda Y, Suehiro T, Inoue M, et al：Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism　47：598-602, 1998

14) Inoue M, Suehiro T, Nakamura T, et al：Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism　49：1400-1405, 2000

15) Abbott CA, Mackness MI, Kumar S, et al：Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol　15：1812-1818, 1995

16) Soran H, Younis NN, Charlton-Menys V, et al：Variation in paraoxonase-1 activity and atherosclerosis. Curr Opin Lipidol　20：265-274, 2009

17) Tsuzura S, Ikeda Y, Suehiro T, et al：Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism　53：297-302, 2004

)gene transcription in HepG2 cells.　176：279-287, 2004

19) Ikeda Y, Suehiro T, Arii K, et al：High glucose induces transactivation of the human paraoxonase 1 gene in hepatocytes. Metabolism　57：1725-1732, 2008

20) Ikeda Y, Inoue M, Suehiro T, et al：Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol　46：239-242, 2009

21) Suehiro T, Ikeda Y, Shiinoki T, et al：Serum paraoxonase(PON1)concentration in patients undergoing hemodialysis. J Atheroscler Thromb　9：133-138, 2002

22) Ikeda Y, Suehiro T, Itahara T, et al：Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol　67：358-365, 2007

23) Wheeler JG, Keavney BD, Watkins H, et al：Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls：meta-analysis of 43 studies. Lancet　363：689-695, 2004

24) Mackness B, Durrington P, McElduff P, et al：Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation　107：2775-2779, 2003

)gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA　299：1265-1276, 2008

26) Ferré N, Camps J, Prats E, et al：Serum paraoxonase activity：a new additional test for the improved evaluation of chronic liver damage. Clin Chem　48：261-268, 2002

27) Kumon Y, Suehiro T, Ikeda Y, et al：Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1β and tumor necrosis factor-α, but is upregulated by interleukin-6. Life Sci　73：2807-2815, 2003

28) Tanimoto N, Kumon Y, Suehiro T, et al：Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci　72：2877-2885, 2003

29) Arii K, Suehiro T, Ota K, et al：Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis　202：439-445, 2009